Table 1 Baseline characteristics

Age, years

44

19–102

BMI, kg/m²

25

15–77

FIGO 2009 stage

 IA2

57

2.6

 IB1

1554

69.5

 IB2

349

15.6

 IIA1

158

7.1

 IIA2

118

5.3

Tumour size, mm

30

0–150

Histology

 Squamous cell carcinoma

1487

66.5

 Adenocarcinoma

602

26.9

 Adenosquamous cell carcinoma

100

4.5

 Neuroendocrine carcinoma

35

1.6

 Other

12

0.5

Type of imaging

 MRI

1676

75.0

 CT

926

41.4

 [¹⁸F]FDG-PET-CT

379

17.0

 MRI and CT

384

17.2

 MRI and [¹⁸F]FDG-PET-CT

314

14.0

 CT and [¹⁸F]FDG-PET-CT

106

4.7

 MRI, CT, and [¹⁸F]FDG-PET-CT

59

2.5

Short-axis of suspicious pelvic node, mm^a

10

5–50

Short-axis of suspicious common iliac node, mm^a

9

6–29

Patient-based nodal status on MRI

 Negative

1390

82.9

 Inconclusive

89

5.3

 Positive

197

11.8

Patient-based nodal status on CT

 Negative

778

84.0

 Inconclusive

53

5.7

 Positive

95

10.3

Patient-based nodal status on [¹⁸F]FDG-PET-CT

 Negative

196

51.7

 Inconclusive

21

5.5

 Positive

162

42.7

Region with positive nodal status on imaging^b

 Pelvic

393

17.7

 Common iliac

54

2.4

 Para-aortic

70

3.1

Patient-based nodal status on pathology

 Negative

1240

55.5

 Positive

317

14.2

 Unknown

679

30.4

Time between imaging and pathological examination, days

 MRI

25

1–56

 CT

26

1–56

 [¹⁸F]FDG-PET-CT

20

0–44

Nodal examination

 Absent

679

30.4

 Lymphadenectomy

1517

67.8

 Nodal debulking

32

1.4

 Biopsy/fine-needle aspiration

2

0.1

 Intraoperative frozen section

4

0.2

 Sentinel node biopsy only

2

0.1